• Purple Biotech appointed director Isaac Israel as interim CEO effective Oct. 5, 2026, pending selection of a permanent chief executive.
• Israel previously served as CEO from Oct. 2012 to July 2022, advised the company since Oct. 2022, led as acting CEO March–August 2023.
• He previously ran BeeContact as founding CEO from 2001 to 2007, later founded Uneri Capital, a capital markets and healthcare consultancy.
• Outgoing CEO Gil Efron will shift to executive director, head of corporate development effective Oct. 5, 2026, while remaining on the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106852), on October 05, 2026, and is solely responsible for the information contained therein.